Tagged with ICH

Switzerland In February 2020, US giant MSD announced the launch of a new site in Zurich specialising in R&D, data management, and commercialisation, foregrounding the company’s commitment to Switzerland. MSD employs over 1000 people in Switzerland across five sites in local, regional, and global functions, engages in 25 in-country clinical trials…

Switzerland After an illustrious career in oncology R&D, contributing greatly to the development of cutting-edge cancer therapies at Novartis and Gilead, Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019. In a recent conversation with PharmaBoardroom, Riva explained why he took on this unique new opportunity at…

Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download.   Long heralded as an innovation powerhouse able to hold its own against the…

Switzerland Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019, leaving behind a storied career in oncology R&D at Novartis and Gilead. In an exclusive interview, Riva outlines his motivations behind taking on this new challenge, how the company’s approach to oncology treatment differs from  – and…

Japan Japan’s pharma market is one of the world’s biggest, with a value of around USD 95 billion, according to figures from the country’s Ministry of Health, Labour and Welfare (MHLW). Japanese firms have a particularly strong standing in their home market, making up six of the country’s top ten pharma…

Talent Four Belgium country managers for some of the world’s largest pharma companies give their words of wisdom for women starting out in the industry.   “Focus on your strengths” Sonja Willems, managing director for Janssen in Belgium, the Netherlands, and Luxembourg (Benelux) shares her wisdom for people building their careers…

Belgium Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an update on the affiliate’s development since its establishment in 2012. De Waslche goes on to speak about the unique cluster dynamic which comes with managing the three markets and also highlights her priorities to…

CEE With a footprint of over 20 years in the Czech Republic, Gedeon Richter’s affiliate here is a key pillar to the company’s success in the Central Eastern European region. Corina Croitoru, Managing Director for the Czech Republic and Slovakia, evaluates the challenges that come with bringing to market medicines on…

Hungary As the only one of Hungary’s four historical pharmaceutical manufactures to have resisted international acquisition, Gedeon Richter stands alone as the country’s national champion. However, the company does not exist in a vacuum and, like many globally active mid-cap pharma players, establishing partnerships across the entire value chain has been…

Hungary Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s first company-developed biosimilar in Japan.   Our advancement in biotechnology has been a key development for Gedeon Richter this year…

Hungary The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of  Prime Minister Viktor Orbán. Here, we highlight four Hungarian pharma champions and their evolving strategies.   Beres Béres Pharmaceuticals was conceived from…

Hungary Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in biologics R&D.   Biosimilars in Europe Over the past decade, over 80 biologic molecules have been launched worldwide. By 2020…